Clinical trials: Pediatric Acute Leukemia
B Cell Leukemias, B Cell Lymphomas
CD22 Redirected Autologous T Cells for ALL
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in…
- Trial name
- NCT02650414
- Testing
- Cohort 1, Cohorts 2, Cohort 3
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Acute Myeloid Leukemia
MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia
This is a non-therapeutic study. Pediatric AML patients undergoing HCT with a myeloablative preparative regimen may be enrolled. Subjects can be enrolled 10-40 days prior to HCT.
- Trial name
- NCT01385787
- Where
- 38 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Acute Pain, Pediatric ALL
VR-PAT and fNIRS to Identify CNS Biomarkers of Pain
This study aims to use functional near-infrared spectroscopy (fNIRS) to identify and quantify pain biomarkers during burn dressing changes and pain relief induced by virtual reality (VR).
- Conditions
- Acute Pain, Pediatric ALL, Procedural Pain, Burns
- Trial name
- NCT06303687
- Testing
- VR-PAT
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Nationwide Children's Hospital
Acute Lymphoblastic Leukemia
Nutritional Status in Children With ALL in Guatemala
This study proposes to investigate the association of nutritional status of a children assessed by body mass index (BMI), triceps skinfold thickness (TSFT), and mid upper arm circumference (MUAC), with body composition, measured…
- Trial name
- NCT03471416
- Where
- Guatemala
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Columbia University
Hodgkin Lymphoma, Lymphocytic Leukemia
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
Background: Allogeneic blood and marrow stem cell transplantation (BMT) plays an important role in the curative treatment of a number of pediatric malignancies.
- Conditions
- Hodgkin Lymphoma, Lymphocytic Leukemia, Mixed Cell Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00013533
- Testing
- Stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
This is a pilot study using decitabine and vorinostat before and during chemotherapy with vincristine, dexamethasone, mitoxantrone, and peg-asparaginase in pediatric patients with acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Precursor B-Cell Lymphoblastic Leukemia, Precursor T-Cell Lymphoblastic Leukemia
- Trial name
- NCT01483690
- Testing
- Decitabine, Vorinostat, Vincristine
- Where
- 28 sites in United States, Australia
- Volunteers
- 23 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT.
- Conditions
- Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute, Myeloproliferative-Myelodysplastic Diseases
- Trial name
- NCT00619879
- Testing
- Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients, Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies, Hematopoietic Progenitor Cell Transplantation (HPCT)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Melanoma Stage III, B-cell Non Hodgkin Lymphoma
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.
- Conditions
- Melanoma Stage III, B-cell Non Hodgkin Lymphoma, Pediatric ALL, Childhood Non-Hodgkin Lymphoma
- Trial name
- LONGSAFE (NCT06508775)
- Testing
- MB-CART19.1, MB-CART20.1, MB-CART2019.1
- Where
- 7 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Miltenyi Biomedicine GmbH
Leukemia
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Several groups, especially the PETHEMA group (in their LPA96 and 99 trials), obtained low relapse rates in newly diagnosed Acute Promyelocytic Leukemia (APL) patients by combining ll-transretinoic acid (ATRA) and anthracyclines…
- Trial name
- Ara-C (NCT01191541)
- Testing
- DNR:, Ara-c
- Where
- 2 sites in China
- Volunteers
- 65 people
- Sponsor
- Xiaofan Zhu
Acute Lymphoblastic Leukemia, Pediatric
MRD Detection by NGS in Pediatric B-ALL
This retrospective analysis aims to investigate pediatric patients with B-cell acute lymphoblastic leukemia who were detected for minimal residual disease (MRD) using next-generation sequencing (NGS).
- Trial name
- NCT05973032
- Testing
- MRD
- Where
- China
- Volunteers
- 430 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Gait, Drop Foot, Chemotherapy-induced Peripheral Neuropathy
Impact of an Orthotic Intervention in Children With Peripheral Neuropathy
This research study will investigate the effect of two orthotic (brace) devices for the ankle and foot on walking and ankle flexibility in children with cancer not involving the brain or spinal cord.
- Conditions
- Gait, Drop Foot, Chemotherapy-induced Peripheral Neuropathy, Acute Lymphocytic Leukemia, Pediatric, Rhabdomyosarcoma
- Trial name
- IOPN (NCT03655587)
- Testing
- Solid ankle foot orthotic, Resting night splint
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Leukemia
Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia
The primary objective of phase 1 of this study is to establish the recommended phase II dose (RP2D). The primary objective of phase 2 of this study is to evaluate the safety and efficacy of bendamustine at the recommended…
- Trial name
- NCT01088984
- Testing
- Bendamustine
- Where
- 50 sites in United States, Australia and 10 more
- Volunteers
- 43 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Leukemia, Lymphoma
Interferon Alfa in Treating Children With HIV-Related Cancer
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating children with an HIV-related cancer including leukemia, non-Hodgkin's…
- Conditions
- Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00002621
- Testing
- recombinant interferon alfa
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 8 people
- Sponsor
- Children's Oncology Group
Acute Lymphoblastic Leukemia
Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALL
This is a single arm, open-label, multi-center, phase II study to determine the activity and the safety of a therapeutic strategy that allows a second CARCIK-CD19 cells infusion, driven by the status of disease from one month…
- Trial name
- NCT05252403
- Testing
- PTG-CARCIK-CD19
- Where
- 2 sites in Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Leukemia, Lymphoblastic, Acute, Pediatric
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Trial name
- NCT00042341
- Testing
- clofarabine (IV formulation)
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Graft-versus-Host-Disease, Leukemia
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
This study will validate a previously developed pediatric prognostic biomarker algorithm aimed at improving prediction of risk for the later development of chronic graft-versus-host disease (cGvHD) in children and young adults…
- Conditions
- Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer
- Trial name
- NCT04372524
- Where
- 16 sites in United States, Canada
- Volunteers
- 350 people
- Sponsor
- University of British Columbia
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2…
- Trial name
- CAMS-Ph+ B-ALL (NCT07152041)
- Testing
- olverembatinib
- Where
- 24 sites in China, Hong Kong
- Volunteers
- 150 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Myeloid Leukemia
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
This study will examine the appropriate dose and side effects of dasatinib, when it is given with the standard of care chemotherapy for children and adolescents with Acute Myeloid Leukemia (AML).
- Trial name
- NCT02680951
- Testing
- Dasatinib, Fludarabine, Cytarabine
- Sponsor
- Emory University
Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
This phase I trial is studying the side effects and best dose of vorinostat when given together with isotretinoin in treating young patients with recurrent or refractory solid tumors, lymphoma, or leukemia.
- Conditions
- Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00217412
- Testing
- vorinostat, isotretinoin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)